1-[(4-氯苯基)甲基]-4-(3-氯丙基)哌嗪 | 39577-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[(4-氯苯基)甲基]-4-(3-氯丙基)哌嗪
• 英文名称: 1-(4-chlorobenzyl)-4-(3-chloropropyl)piperazine
• 英文别名: 1-[(4-chlorophenyl)methyl]-4-(3-chloropropyl)piperazine
• CAS: 39577-03-2
• 化学式: C₁₄H₂₀Cl₂N₂
• 分子量: 287.232
• InChiKey: GQMHYGCWUDYARM-UHFFFAOYSA-N

物化性质

• 沸点：
  150 °C(Press: 0.5 Torr)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[(4-氯苯基)甲基]-4-(3-氯丙基)哌嗪 在 potassium carbonate 作用下， 以 四氢呋喃 、 吡啶 、 N,N-二甲基甲酰胺 为溶剂， 反应 49.0h， 生成 1-(3-{3-[4-(4-Chloro-benzyl)-piperazin-1-yl]-propyl}-5-cyano-3H-imidazol-4-yl)-3-methyl-urea
  参考文献：
  名称：

  Grozinger; Freter; Farina, European Journal of Medicinal Chemistry, 1983, vol. 18, # 3, p. 221 - 226

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯氯苄 在 三乙胺 作用下， 以 乙醇 为溶剂， 生成 1-[(4-氯苯基)甲基]-4-(3-氯丙基)哌嗪
  参考文献：
  名称：

  Witte, Arzneimittel-Forschung/Drug Research, 1989, vol. 39, # 10 A, p. 1309 - 1309

  摘要：

  DOI：

文献信息

• Synthesis and Analgesic Activity of Some Condensed Analogs of Anpirtoline
  作者：Stanislav Rádl、Lenka Kovárová、Petr Hezky、Václav Vosátka、Otylie Königová、Jan Proška、Ivan Krejcí

  DOI：10.1002/(sici)1521-4184(19996)332:6<208::aid-ardp208>3.0.co;2-0

  日期：1999.6

  New condensed derivatives of anpirtoline, in which the pyridine ring is replaced with quinoline, isoquinoline, quinazoline, and phthalazine nuclei, have been synthesized. Their receptor binding profiles (5‐HT1A, 5‐HT1B) and analgesic activity (hot plate, acetic acid induced writhing) have been studied. The analgesic activity of compounds 7d, 8b, 8c, and 8e are at least comparable to that of the clinically

  已经合成了新的 Anpirtoline 缩合衍生物，其中吡啶环被喹啉、异喹啉、喹唑啉和酞嗪核取代。已经研究了它们的受体结合谱（5-HT1A、5-HT1B）和镇痛活性（热板、乙酸诱导的扭体）。在相同条件下，化合物7d、8b、8c和8e的镇痛活性至少与临床使用的药物氟吡汀和曲马多相当。
• Bis(piperazinyl or homopiperazinyl)alkanes
  申请人：Boehringer Ingelheim Ltd.

  公开号：US04725597A1

  公开（公告）日：1988-02-16

  Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently hydrogen, alkyl of 1 to 4 carbon atoms, hydroxyl, alkoxy of 1 to 4 carbon atoms, alkanoyloxy of 1 to 4 carbon atoms, halogen, trihalomethyl, di(lower alkyl of 1 to 4 carbon atoms)amino, (alkoxy of 1 to 4 carbon atoms)carbonyl, nitro, cyano or alkanoyl of 1 to 3 carbon atoms; R.sub.7 and R.sub.8 are independently hydrogen, methyl, hydroxyl, carboxyl, (alkoxy of 1 to 4 carbon atoms)carbonyl, hydroxymethyl, phenyl, or p-chlorophenyl; R.sub.9 and R.sub.10 are independently hydrogen or methyl; j and k are independently 0, 1, 2, or 3, their sum being no more than 4; m and n are independently 0, 1, 2, or 3, their sum being no more than 4; A is --CH.sub.2 -- or --CH.sub.2 --CH.sub.2 --; R.sub.7 and R.sub.9 together are oxo, provided k is other than o; R.sub.8 and R.sub.10 together are oxo, provided m is other than o; R.sub.11 and R.sub.12 independently represent hydrogen or one to four methyl substituents on the carbon atoms of the piperazine ring (A=--CH.sub.2 --); R.sub.13, R.sub.14, R.sub.15, and R.sub.16 are independently hydrogen or methyl; R.sub.13 and R.sub.14 together are oxo; R.sub.15 and R.sub.16 together are oxo; and X is alkylene of 1 to 2 carbon atoms, optionally hydroxy-substituted; or a non-toxic, pharmacologically acceptable acid addition salt thereof, are useful as antiallergic and anti-inflammatory agents.

  式为##STR1##的化合物，其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.6独立地为氢、1至4个碳原子的烷基、羟基、1至4个碳原子的烷氧基、1至4个碳原子的烷酰氧基、卤素、三卤甲基、1至4个碳原子的低烷基)氨基、(1至4个碳原子的烷氧基)羰基、硝基、氰基或1至3个碳原子的烷酰基；R.sub.7和R.sub.8独立地为氢、甲基、羟基、羧基、(1至4个碳原子的烷氧基)羰基、羟甲基、苯基或对氯苯基；R.sub.9和R.sub.10独立地为氢或甲基；j和k独立地为0、1、2或3，它们的和不超过4；m和n独立地为0、1、2或3，它们的和不超过4；A为--CH.sub.2 --或--CH.sub.2 --CH.sub.2 --；R.sub.7和R.sub.9一起为氧代，条件是k不等于o；R.sub.8和R.sub.10一起为氧代，条件是m不等于o；R.sub.11和R.sub.12独立地表示对哌嗪环的碳原子上的氢或一个到四个甲基取代基（A=--CH.sub.2 --）；R.sub.13、R.sub.14、R.sub.15和R.sub.16独立地为氢或甲基；R.sub.13和R.sub.14一起为氧代；R.sub.15和R.sub.16一起为氧代；X为1至2个碳原子的烷基，可选地为羟基取代；或其非毒性、药理学上可接受的酸盐，可用作抗过敏和抗炎药物。
• 3,4-Dihydro-2H-naphthalene-1-one-5-oxypropyl-piperazine compounds
  申请人：Boehringer Mannheim G.m.b.H.

  公开号：US03932411A1

  公开（公告）日：1976-01-13

  New 3,4-dihydro-2H-naphthalene-1-one-5-oxypropyl-piperazine derivatives of the formula: ##SPC1## Wherein A is hydrogen or hydroxyl; X is hydrogen, halogen, alkyl or Alkoxy; and n is 0, 1 or 2; And the pharmacologically compatible salts thereof; are outstandingly effective in blood pressure depressing and tranquilizing or sedative therapy; further, these compounds have antioedematous action and reduce capillary permeability.

  新的3,4-二氢-2H-萘酮-5-氧丙基-哌嗪衍生物的化学式如下：##SPC1## 其中A为氢或羟基；X为氢、卤素、烷基或烷氧基；n为0、1或2；以及其药理学兼容盐；在降低血压和镇静或催眠疗法方面具有杰出的效果；此外，这些化合物具有抗水肿作用并减少毛细血管通透性。
• Benzopyranones, a method for producing them and uses therefor
  申请人：Dr. Willmar Schwabe GmbH & Co.

  公开号：US05428038A1

  公开（公告）日：1995-06-27

  Novel 2H-1-benzopyran-2-ones (coumarin derivatives) of the general formula (I) are provided: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are defined as in the specification, and the addition compounds thereof with physiologically compatible acids, intermediates and methods for the preparation thereof. The coumarin compounds possess a neuroprotective and anti-allergic action.

  提供一般式(I)的新型2H-1-苯并吡喃-2-酮（香豆素衍生物）：##STR1## 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、X和Y的定义如规范中所述，并与生理兼容酸的加合物、中间体及其制备方法。香豆素化合物具有神经保护和抗过敏作用。
• Heterocyclic coumarin derivatives
  申请人：Beecham Group Limited

  公开号：US04263299A1

  公开（公告）日：1981-04-21

  A compound of formula (I): ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a bond or oxygen; Y is --(CH.sub.2).sub.n -- where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen; may be used in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay-fever, rhinitis and allergic eczema.

  化合物的结构式（I）：##STR1##及其药学上可接受的盐，其中R是氢或含有最多6个碳原子的烷基基团；X是键或氧；Y是--(CH.sub.2).sub.n--，其中n为0或1至5的整数，其中一个未与氮原子结合的碳原子可以选择性地被羟基取代；Z是氢或卤素；可用于预防和治疗由过敏反应介质控制症状的疾病，例如哮喘、花粉症、鼻炎和过敏性湿疹。